These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34275546)

  • 1. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature.
    Pagonabarraga J; Tinazzi M; Caccia C; Jost WH
    J Clin Neurosci; 2021 Aug; 90():178-183. PubMed ID: 34275546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
    Müller T
    Expert Rev Neurother; 2013 Sep; 13(9):969-77. PubMed ID: 24053341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safinamide for the treatment of Parkinson's disease.
    Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
    Cattaneo C; Jost WH; Bonizzoni E
    J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
    Sciaccaluga M; Mazzocchetti P; Bastioli G; Ghiglieri V; Cardinale A; Mosci P; Caccia C; Keywood C; Melloni E; Padoani G; Vailati S; Picconi B; Calabresi P; Tozzi A
    Neuropharmacology; 2020 Jun; 170():108024. PubMed ID: 32142791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safinamide for the treatment of Parkinson's disease.
    deSouza RM; Schapira A
    Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study.
    De Micco R; Satolli S; Siciliano M; De Mase A; Giordano A; Tedeschi G; Tessitore A
    Neurol Sci; 2022 Jan; 43(1):357-364. PubMed ID: 34031800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Abreu D; Ferreira JJ
    Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
    Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
    Abdelalem Aziz Ahmed M
    F1000Res; 2019; 8():2078. PubMed ID: 32431802
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
    Schapira AH; Fox SH; Hauser RA; Jankovic J; Jost WH; Kenney C; Kulisevsky J; Pahwa R; Poewe W; Anand R
    JAMA Neurol; 2017 Feb; 74(2):216-224. PubMed ID: 27942720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
    Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
    Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safinamide: a new hope for Parkinson's disease?
    Teixeira FG; Gago MF; Marques P; Moreira PS; Magalhães R; Sousa N; Salgado AJ
    Drug Discov Today; 2018 Mar; 23(3):736-744. PubMed ID: 29339106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
    Gardoni F; Morari M; Kulisevsky J; Brugnoli A; Novello S; Pisanò CA; Caccia C; Mellone M; Melloni E; Padoani G; Sosti V; Vailati S; Keywood C
    J Pharmacol Exp Ther; 2018 Dec; 367(3):442-451. PubMed ID: 30291173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safinamide: first global approval.
    Deeks ED
    Drugs; 2015 Apr; 75(6):705-11. PubMed ID: 25851099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.